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CAPTOPRIL PHARMACOKINETICS IN CHRONIC HEART FAIL- 
URE: CORRELATION WITH ACUTE HEMODYNAMIC AND HOR- 
MONAL RESPONSE. Robert J. Cody MD; Andrew 
Covit. MD: Garv S&ter, MD; Gar; Williams, MD. 
Corneil University Medical Center New York, N.Y. 
There is no pharmacokinetic data regarding acute 
response to captopril (CAP) in congestive heart 
failure (CHF), and absence of response might re- 
present inadequate dosage or minimal renin- 
angiotensin system (RAS) activity. We therefore 
correlated the response of the RAS and hemody- 
namic change with CAP blood levels in six pa- 
tients after a 25 mg. oral dose. Blood levels 
(ng/ml) were: 26 c.33 hr.), 58 c.67 hr.), 81 
(1.0 hr.), 65 (1.5.hr.1, 51 (2.0 hr.), 24 (3.0 
hr.), 10 (4.0 hr.), and 0.7 (8.0 hr.). For the 
group, maximum concentration was 99f19 at 1.2f.2 
hr. Decrease of AP (78+3 to 66f6 mm Hg.), PWP 
(20*3 to 12+3 mm Hg.), 
s/s/cm-5), 9 
SVR (1492f184 to 1223?195 
nd increase of CI (2.09t.15 to 2.3Ff 
.14 L/min/!l 1, and SI (28f3 to 34f4 ml) occurred 
at 1.0 hr. These return to baseline by 4.0 hr. 
Compared with control values, plasma renin (ng/ 
ml/hr) was increased (8f3 to 44?10), and plasma 
aldosterone (ng %) decreased (lo+2 to 6+1) at 
1.0 hr.; both p<.O5. Hoeever, extent of hemody- 
namic improvement was correlated with baseline 
plasma renin: AP (r=.-780), PWP (r=-.606), SVR 
(r=-.856), SI (r=.727). In summary, oral CAP is 
readily absorbed in CHF, with peak levels at 1.2 
hr. Levels correlated with hemodynamic effects 
and RAS blockade. However, baseline RAS activ- 
ity was a better predictor of the extent of re- 
sponse; patients with minimal activity showed 
minimal hemodynamic improvement despite adequate 
blood levels. 
THE EFFECT OF CAPTOPRIL ON SYSTEMIC AND RENAL HRMO- 
DYNAMICS IN PATIENTS WITH CONGESTIVE HEART FAILURE. 
Eric R. Powers, MD; Jane E. Stone, MD; Kenneth S. 
tlannerman, MD; Dennis S. Reison, MD; Melvin B. Weiss, 
MD, FACC; Robert R. Sciacca, EngScD; Paul J. Cannon, 
MD, FACC, Columbia University, New York, N.Y. 
Recent studies have demonst.rated that Captopril (C), 
an oral angiotensin converting malyme inhibitor, can iru- 
prove Lena1 perfusion and function in patients with con- 
gestive heart failure (CHF). We studied the effects of 
C on systemic and renal hemodynamics, and sodium ex- 
cretion in nine patients With CHF. Systemic hemodynamics 
were measured before and one hour after a 25mg cral dose 
of Captoprll. Crentinine clearance, renal blood flow 
(113l-hippuran clearance) and sodium excretion were 
measured the ddy before and the day after initiation of 
therapy. The results are given below (mean + SD). 
Pre Post 
heart rate (beatsfmin) 75?13 73+16 
cardiac output (L/min) 3.6il.O 4.2t1.3* 
pulmonary arrery pressure (mmHg) 3128 23+10* 
pulmonary wedge pressure (mmHg) 18?6 12+9* 
arterial pressure (mmHg) 77ilO 59t13* 
systemic vascular resistance 
(dyne-set-cm-5) 1706i616 1225?542 
creatinine clearance (mllmin) 58?24 62t34 
renal blood flow (ml/min) 387~251 3451147 
filtration fraction .19+.oa 19+.09 
sodium excretion (meq/day) 39?39 '26i17 
*significant change with Captopril (pc.05) 
Thus, despite a significant improvemeht in systemic 
hemodynamics, C did not result in a change in filtration 
fraction, an improved sodium excreticn or a redistri- 
bution of the cardiac output toward the kidney. These 
data demonstrate that Captopril may not improve renal 
hemodynamics and function in all patients with CHF. 
CONTROLLEDTRlALOFCAPTOPRlLFOR HEART FAILURE: 
EFFECT8 ON HEMODYNAMICS, SCINTIGRAPHY AND 
EXERCISETOLERANCE. Barry Barry Massie,MD, 
FACC, Nina Topic, RN. VA Hospital and University of California 
San Francisco, CA. 
To rigorously assess the efficacy of captopril (CAP) in 
chronic heart failure (CHF), we measured the.acute effect of 
open label (OL) CAP on hemodynamic (HEMO) and scintigraphic 
(SCINT) indices in 12 patients (PTS) with Class 3 CHF maintained 
on digoxin and diuretics. Then, in a double-blinded 3 month (3M) 
trial, 7 PTS were randomized to CAP, 12.5-100 mg tid (Group 1) 
and 5 to placebo (PL, Group 2). Serial SCINT, upright bicycle 
exercise (Ex) tests and repeat HEM0 (in 9/10 survivors) were 
performed. 
LVFP SVI EDV VOJml/kg)ExDur(min) 
GPl-pre 25f10 28f9 %7 417*62 11.8k2.6 8.6t2.1 
CAP-OL 16f8# 36f7* 23+6# 371?74*12.3?2.3 9.1t1.9 
CAP-3M 16f7# 34+7# 24t8# 377f79*15.6f2.7*11.8+1.3# 
GPS-pre 3cW5 19f6 18f5 369+_86 ll.lQ.5 6.8tl.O 
CAP-OL 18t6 30i9* 21*4* 338?71*11.1t1.7 5.7t1.8 
PL-3M 29f5 18t5 17+6 363284 10.3f3.6 5.9t4.8 
Significant change from control: *=p<.O5; #=p< .Ol 
Acutely, OL CAP reduced left ventricular filling pressure 
(LVFP) and increased stroke volume index (WI) in both groups. LV 
ejection fraction (EF) rose slightly, while LV end diastolic volume 
(EDV) declined. Maximum V@ did not change concurrently with 
this acute hemodynamic improvement. After 3M LVFP remained 
lower and SVI higher in PTS on CAP, but not in PL PTS. The acute 
improvement in EF and EDV also was sustained only in PTS on 
CAP. PTS on CAP exhibited an increase in Rx duration and a 
corresponding rise in maximum VOe at 3M, while exercise 
tolerance did not change on PL. Three PT§ markedly worsened on 
PL, one of whom diedsuddenly and a second who died shortly 
after being withdrawn from the study. These findings demonstrate 
the acute efficacy and long term benefits of CAP therapy for 
CHF. 
CHRONIC ADJUNCTIVE TRIMAZOSIN VASODILATOR THERAPY IN HEART 
FAILURE: A SIX MONTH DOUBLE-BLIND PLACEBO CONTROLLED 
RANDOMIZED TRIAL 
Philip C. Kirlin, IfD; Sunil Das, MD; Theresa Johnson, RN; 
Mary Kay Foley, RN; Ka Lo, MD; Bertram Pitt, 14D, FACC, 
University of Michigan, Ann Arbor, Michigan 
Trimazosin(T) is an alpha-blocking vasodilating agent with 
demonstrated benefit for up to 2 months(mo) in heart fail- 
ure(HF). In order to assess longer term effects of T, 16 
patients(pts) with chronic functional class II-III HF de- 
spite digitalis and diuretic were randomized to 6 mo dou- 
ble-blind adjunctive T(n=E) or placebo(P)(n=8) with simul- 
taneous noninvasive radionuclide and invasive hemodynamic 
assessment. CI(L/min/m2), PA wedge pressure(PAW)(mmHg), 
LV ejection fraction(LVEF)(%), LV end-diastolic and end- 
systolic volume index(EDVI,ESVI)(ml/m2) and systemic vas- 
cular and pulmonary arteriolar resistance index(SVRI,PARI) 
(dsc-5/m2) were determined at supine rest(R) and maximal 
bicycle ergometer exercise(E): (&SD; *=pz.O5,paired t) 
T CI PAW LVEF EDVI ESVI SVRI PAR1 
Base- i 2.2.4 18+9 19+4 156?33 128?30 2939+39440289 
line E 4.3+1 34?9 21+13206?109 173+105 2097?36039@188 
6 mo R 2.4t.6 18?13 24r9 140?45 108?43 32Gai64539A179 
E 4.5il 29t9* 2&10*144+46* 110+46* 2022136141H258 
E 
Base- R 2.4k.4 17t9 30+14122+46 90r44 32352831 37ti283 
line E 4.7+2 37?8 26+10150+62 llL+80 2238t966 28l?242 
6 mo R 2.6i.8 18+9 28r15174+53 131?60 3404?1999436?462 
E 5.221 25ill* 28+13164+51 123+61 13071330285?202 
T pts received signifiqantly greater diuretic dose increas 
es compared to P (+97% vs -8%, pc.03) to maintain stable 
body weight. 
Thus, adjunctive T improved E but not R hemodynamics at 6 
mo compared to digitalis and diuretic alone. 
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